Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 17/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 17/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 17/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 16/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tofimilast SCHEMBL4914697 | 0.87 | PDE4A (0.86) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL6839751 | 0.81 | PDE4A (0.79) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL6052681 | 0.76 | PDE4A (0.66) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL6358572 | 0.76 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| Tofimilast SCHEMBL230762 | 0.76 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL84865 | 0.67 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL7374352 | 0.66 | PDE4A (0.49) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL14455896 | 0.66 | PDE4A (0.84) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL7369320 | 0.65 | PDE4A (0.48) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL6638544 | 0.65 | PDE4A (0.54) | PDE4APDE4BPDE4DPDE4CADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 748 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | claimed |
| US-20080292562-A1 | Medicaments For Inhalation Comprising Pde IV Inhibitors and Enantiomerically Pure Glycopyrrolate Salts | PIEPER MICHAEL P | 2008-11-27 | — | — | US | claimed |
| EP-1901776-A1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE | Boehringer Ingelheim International GmbH (DE) | 2008-03-26 | — | — | EP | claimed |
| EP-1799205-A1 | MEDICAMENTS FOR INHALATION COMPRISING PDE IV INHIBITORS AND ENANTIOMERCALLY PURE GLYCOPYRROLATE SALTS | Boehringer Ingelheim International GmbH (DE) | 2007-06-27 | — | — | EP | claimed |
| EP-1781298-A1 | PHARMACEUTICAL COMBINATIONS CONTAINING BENZOXAZINE FOR TREATING RESPIRATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-05-09 | — | — | EP | claimed |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | US | claimed |
| WO-2007003554-A1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE. | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | claimed |
| JP-2007500148-A | — | — | 2007-01-11 | — | — | JP | claimed |
| US-20060286041-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-21 | — | — | US | claimed |
| US-20060270667-A1 | NOVEL MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-30 | — | — | US | claimed |
| EP-1397135-A2 | COMBINATION OF A PDE4 INHIBITOR AND TIOTROPIUM OR DERIVATIVE THEREOF FOR TREATING OBSTRUCTIVE AIRWAYS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-03-17 | — | — | EP | claimed |
| EP-1395288-A1 | A PDE 4 INHIBITOR AND AN ANTI-CHOLINERGIC AGENT IN COMBINATION FOR TREATING OBSTRUCTIVE AIRWAYS DISEASES | PFIZER INC. (US) | 2004-03-10 | — | — | EP | claimed |
| EP-1048667-B1 | Process for preparing 8-cyclopentyl-6-ethyl-3-(substituted)-5,8-dihydro-4H-1,2,3A,7,8-pentaaza-as-indacenes and intermediates useful therein | PFIZER PROD INC (US) | 2003-10-22 | — | — | EP | claimed |
| US-20030119862-A1 | Pharmaceutical combination | PFIZER, INC. | 2003-06-26 | — | — | US | claimed |
| US-20030064031-A1 | For therapy of respiratory diseases such as asthma or chronic obstructive pulmonary disease | PFIZER INC. | 2003-04-03 | — | — | US | claimed |
| WO-2002096423-A2 | COMBINATION OF A PDE4 INHIBITOR AND TIOTROPIUM OR DERIVATE THEREOF FOR TREATING OBSTRUCTIVE AIRWAYS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-12-05 | — | — | WO | claimed |
| WO-2002096463-A1 | A PDE 4 INHIBITOR AND AN ANTI-CHOLINERGIC AGENT IN COMBINATION FOR TREATING OBSTRUCTIVE AIRWAYS DISEASES | PFIZER INC. (US) | 2002-12-05 | — | — | WO | claimed |
| US-6326495-B2 | HEATING A MIXTURE OF CAPROLACTONE AND P-METHOXYBENZYLAMINE; CYCLIZATION | PFIZER INC. | 2001-12-04 | — | — | US | claimed |
| US-20010039347-A1 | Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4h-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein | PFIZER PRODUCTS INC. | 2001-11-08 | — | — | US | claimed |
| EP-1048667-A1 | Process for preparing 8-cyclopentyl-6-ethyl-3-(substituted)-5,8-dihydro-4H-1,2,3A,7,8-pentaaza-as-indacenes and intermediates useful therein | Pfizer Products Inc. (US) | 2000-11-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270667-A1 | NOVEL MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | ADRB3, CHRM3, ADRB2 | PDE4A 20/4885PDE4B 10/4885PDE4D 37/4885 |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | ADRB2, ADRA2A, ADRB1 | PDE4A 335/4885PDE4B 285/4885PDE4D 523/4885 |
| US-20030064031-A1 | For therapy of respiratory diseases such as asthma or chronic obstructive pulmonary disease | TMCO1, CHRM3, IL5 | PDE4A 108/4885PDE4B 135/4885PDE4D 172/4885 |
| US-20060286041-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | ABCB1, ABCC4, ABCC1 | PDE4A 687/4885PDE4B 651/4885PDE4D 1704/4885 |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | PDE4A 32/4885PDE4B 21/4885PDE4D 144/4885 |
| US-20080292562-A1 | Medicaments For Inhalation Comprising Pde IV Inhibitors and Enantiomerically Pure Glycopyrrolate Salts | PDE3A, PDE3B, PDE12 | PDE4A 5/4885PDE4B 7/4885PDE4D 11/4885 |
| US-20010039347-A1 | Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4h-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein | ADH1A, ADH1C, OTC | PDE4A 1915/4885PDE4B 2742/4885PDE4D 3155/4885 |
| US-20030119862-A1 | Pharmaceutical combination | PDE4B, PDE4A, ADRB2 | PDE4A 2/4885PDE4B 1/4885PDE4D 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.